Gilead widens battle against alleged counterfeit HIV drug ring
		
		 
		Send a link to a friend  
 
		
		
		 [September 29, 2022] 
		By Brendan Pierson 
		 
		(Reuters) - A federal judge in New York has 
		frozen the assets of dozens of people and entities accused of operating 
		a massive nationwide scheme to distribute counterfeit bottles of Gilead 
		Sciences Inc HIV drugs, including two alleged "kingpins."  
		 
		Gilead, which has been pursuing alleged counterfeiters in a civil 
		lawsuit since last year, said in a court filing unsealed on Wednesday it 
		had uncovered an operation that was "staggering in scope," responsible 
		for sales of hundreds of millions of dollars of counterfeit bottles of 
		its top sellers Descovy, Genvoya and Biktarvy, and other medicines. 
		 
		U.S. District Judge Ann Donnelly's latest asset freeze order, also 
		unsealed on Wednesday, targets more than 50 defendants newly added to 
		Gilead's lawsuit. 
		 
		Many counterfeit bottles contain antiviral pills manufactured by Gilead 
		but illegally bought off the street and repackaged, while some have been 
		found to contain other, potentially dangerous drugs, including the 
		powerful antipsychotic Seroquel, Gilead has said. 
		  
		
		  
		
		 
		HIV drugs accounted for $7.6 billion of Gilead's $12.6 billion revenue 
		in the first half of the year. The company in January warned that more 
		than $250 million of counterfeit drugs had been sold over the last two 
		years, and said it had identified more than 85,000 bottles that were 
		fake or tampered with. 
		
		The newly added defendants include alleged "kingpins" Lazaro Roberto 
		Hernandez, who was arrested on drug counterfeiting and money laundering 
		charges in June as part of a related federal investigation and remains 
		under house arrest, and Armando Herrera, who lives in Florida. 
		 
		[to top of second column] 
			 | 
            
             
            
			  
            
			The logo of Gilead Sciences Inc 
			pharmaceutical company is seen in Oceanside, California, U.S., April 
			29, 2020. REUTERS/Mike Blake/File Photo 
            
			
			
			  "Gilead's ongoing investigation 
			revealed that these two kingpins directed the initial sale of the 
			counterfeits through suppliers created solely to sell counterfeit 
			medications," the company said in a statement on Wednesday.  
			 
			Gilead said it had identified the two men, who took elaborate steps 
			to conceal their identities, by matching approximate locations of 
			their disposable burner cell phones with flight records. 
			 
			The Foster City, California-based company first announced it was 
			pursuing counterfeiters in August 2021, shortly after filing its 
			lawsuit. 
			 
			In addition to the alleged kingpins, the case now includes alleged 
			mid-level leaders and a complex web of shell companies, distributors 
			and pharmacies.  
			 
			It also involves so-called collectors, who pay cash on the street 
			for the bottles used in the scheme, often acquiring them from people 
			who are homeless or suffering from drug addiction, Gilead said. 
			 
			(Reporting By Brendan Pierson in New York and Akriti Sharma in 
			Bengaluru; Editing by Bill Berkrot and Leslie Adler) 
			
			[© 2022 Thomson Reuters. All rights 
				reserved.]  This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			   |